ClinicalTrials.gg
CompletedNCT00159822Updated Jan 20, 2010Results posted

Voriconazole For Chronic Bronchopulmonary Aspergillosis

A Phase 2/3 interventional study of Voriconazole in Aspergillosis, sponsored by Pfizer. Completed at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-01-20.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.

Enrollment
4th of 17
48 · median 24
Started
2005
the only one that year
Phase 2/3
Only one
of the 17
Registered
5th of 17
by date
Lead sponsor
6 of 17
Pfizer

Among the 17 studies testing voriconazole in Aspergillosis, this one is the 4th largest by enrollment, is the only one that started in 2005, is the only one in phase 2/3, and was the 5th registered.

Aspergillosis

134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.

Browse Aspergillosis studies →

Open to participants now

None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →

About voriconazole

Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing voriconazole in Aspergillosis as a file.
02

Study summary

To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary

03

Conditions studied

  • Aspergillosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a chronic bronchopulmonary aspergillosis assessed by a compatible chest imagery (CT scan) and/or an endoscopic lesion sourced by photo, would it be:
  • Complex aspergilloma non primarily operable,
  • Chronic necrotizing pulmonary aspergillosis,
  • Tracheo-bronchial aspergillosis, obstructive or necrotizing/pseudo-membranous.

Exclusion criteria

Exclusion Criteria:

  • Patient with risk factor(s) of cardiac arrhythmia, symptomatic arrhythmia, treated by medication known to prolong , or prolongation of QTc interval > 450 msec in men and > 470 msec in women.
  • Simple aspergilloma with primary indication of surgical treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    1

    Drug: Voriconazole

Interventions

  • Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response. Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis

    Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50 percent on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.

    Time frame: at 6 months of treatment

Secondary outcomes

  1. Number of Subjects With Successful Global Outcome at Month 3 and End of Treatment: Chronic Bronchopulmonary Aspergillosis

    Successful global outcome: composite assessment of radiological and mycological responses; defined as complete (resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline) or partial (reduction in diameter ≥ 50 percent on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion) radiological response and mycological eradication after 3 months of treatment and after 9 or 12 months (in case of extension of treatment period beyond 6 months); no success=criteria not met. Assessment determined by DRC.

    Time frame: Month 3 and End of Treatment (Month 9 or Month 12)

  2. Number of Subjects With Successful Global Outcome at 6 Months: Chronic Necrotizing Pulmonary Aspergillosis (CNPA) and Tracheo-bronchial Aspergillosis

    Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.

    Time frame: at 6 months of treatment

  3. Number of Subjects With Successful Global Outcome at 6 Months: Complex Aspergilloma

    Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.

    Time frame: at 6 months of treatment

  4. Change From Baseline in Respiratory Clinical Signs and Symptoms on Visual Analog Scales (VAS)

    Subject assessment of improvement of respiratory clinical signs and symptoms as indicated by the subject placing a mark on a 10 cm VAS scored 0 (better state of health) to 100 (poor state of health) for cough, dyspnea, sputum, hemoptysis, chest tightness, and nocturnal awakening. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).

    Time frame: Baseline, Month 3, and Month 6, Month 9, or Month 12 [EOT], and End of study ([EOS] EOT + 6 months)

  5. Number of Subjects With Relapse

    Relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \[TDM\] and or endoscopy) and mycologically (histology and or culture and or serology).

    Time frame: During the 6 months following EOT (EOT + 3 months, EOT + 6 months)

  6. Time to Relapse After EOT

    Time (months) to relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \[TDM\] and or endoscopy) and mycologically (histology and or culture and or serology).

    Time frame: During the 6 months following EOT (EOT + 3 months, EOT + 6 months)

  7. Global Survival: Number of Subjects With an Outcome of Death

    Number of subjects with an outcome of death (adverse event with a fatal outcome) through end of study.

    Time frame: Baseline through EOS (EOT + 6 months)

  8. Change From Baseline in Quality of Life (QOL): St. George's Hospital Respiratory Questionnaire

    Subject administered questionnaire to measure improvement in QOL; 50 questions exploring 3 different areas: symptoms, impact on activity profile (activity), and impact on daily life (impacts). Each item in an area is weighted based on empirical data; scores range from lowest possible weight 0 to highest possible weight 100. Scores for each section and total score calculated using score calculation algorithms with higher scores indicating poor health. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).

    Time frame: Baseline, Month 3, and Month 6, Month 9, or Month 12 [EOT], and EOS (EOT + 6 months)

  9. Number of Subjects With Complete or Partial Radiological Response

    Radiological response: based on chest TDM except for tracheo-bronchialaspergillosis which was assessed by bronchoscopy. Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.

    Time frame: Month 3, and Month 6, Month 9, or Month 12 [EOT]

  10. Number of Subjects With Mycological Response of Eradication

    Mycological response: eradication: absence of aspergillus species (spp) in bronchopulmonary samples: sputum, bronchial aspirate or bronchoalveolar lavage (BAL) (negative direct examination \[exam\] and negative culture), and negative histological exam when available; persistence (no eradication): presence of aspergillus spp in any relevant bronchopulmonary samples. Not done (presumed eradication): case reviewed by DRC for any mycological exams not performed to assess if case should constitute presumed eradication (no sputum due to clinical improvement).

    Time frame: Month 3, and Month 6, Month 9, or Month 12 [EOT]

  11. Number of Subjects With Complete or Partial Serological Response

    Serological response: normalization (complete response) defined as return to normal values (≤ 1 arc); partial response defined as significant decrease but not complete (decrease of 2 or more arcs compared to baseline). Complete or partial response summarized as Improvement; based on arc values at visit compared to arc values at baseline (inclusion).

    Time frame: Month 3, and Month 6, Month 9, or Month 12 [EOT]

07

Results

Posted Jan 7, 2010
Limitations and caveats
Study treatment duration is at least 6 months for subjects with best achievable response after 3 months of treatment, of 9 months for subjects with best achievable response after 6 months of treatment and of 12 months in other cases.

Participant flow

18 active centers in France; planned recruitment of 48 minimally immunocompromised or non-immunocompromised subjects with chronic bronchopulmonary aspergillosis.

Voriconazole Treatment Period
Participant flow — Voriconazole Treatment Period
MilestoneVoriconazole
Started48
Completed26
Not completed22
Withdrew: Lack of efficacy3
Withdrew: Adverse event9
Withdrew: Death4
Withdrew: Protocol violation2
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject2
Post-treatment Follow-up Period
Participant flow — Post-treatment Follow-up Period
MilestoneVoriconazole
Started26
Completed23
Not completed3
Withdrew: Death1
Withdrew: Withdrawal by subject1
Withdrew: Reason unspecified1

Outcome measures

PrimaryNumber of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis

Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50 percent on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.

Time frame:
at 6 months of treatment
Reported as:
Number · participants
Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis
participantsVoriconazole
Success13
No success28
Statistical analysis
  • Voriconazole · Percent of subjects with success: 31.7 · 95% CI 18.08 to 48.09Number of subjects with successful global outcomes were summarized and 95% two-sided confidence intervals based on the exact Clopper-Pearson method for the binomial distribution provided.
SecondaryNumber of Subjects With Successful Global Outcome at Month 3 and End of Treatment: Chronic Bronchopulmonary Aspergillosis

Successful global outcome: composite assessment of radiological and mycological responses; defined as complete (resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline) or partial (reduction in diameter ≥ 50 percent on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion) radiological response and mycological eradication after 3 months of treatment and after 9 or 12 months (in case of extension of treatment period beyond 6 months); no success=criteria not met. Assessment determined by DRC.

Time frame:
Month 3 and End of Treatment (Month 9 or Month 12)
Reported as:
Number · participants
Number of Subjects With Successful Global Outcome at Month 3 and End of Treatment: Chronic Bronchopulmonary Aspergillosis
participantsVoriconazole
Month 3 success=yes12
Month 3 success=no24
Month 3 success=missing values5
EOT [LVA] success=yes18
EOT [LVA] success=no23
Statistical analysis
  • Voriconazole · Percent of subjects with success: 33.3 · 95% CI 18.6 to 51.0Number of subjects with successful global outcomes were summarized and 95% two-sided confidence intervals based on the exact Clopper-Pearson method for the binomial distribution provided.
  • Voriconazole · Percent of subjects with success: 43.9 · 95% CI 28.5 to 60.3Number of subjects with successful global outcomes were summarized and 95% two-sided confidence intervals based on the exact Clopper-Pearson method for the binomial distribution provided.
SecondaryNumber of Subjects With Successful Global Outcome at 6 Months: Chronic Necrotizing Pulmonary Aspergillosis (CNPA) and Tracheo-bronchial Aspergillosis

Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.

Time frame:
at 6 months of treatment
Reported as:
Number · participants
Number of Subjects With Successful Global Outcome at 6 Months: Chronic Necrotizing Pulmonary Aspergillosis (CNPA) and Tracheo-bronchial Aspergillosis
participantsVoriconazole
Success10
No success9
SecondaryNumber of Subjects With Successful Global Outcome at 6 Months: Complex Aspergilloma

Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.

Time frame:
at 6 months of treatment
Reported as:
Number · paticipants
Number of Subjects With Successful Global Outcome at 6 Months: Complex Aspergilloma
paticipantsVoriconazole
Success3
No success19
SecondaryChange From Baseline in Respiratory Clinical Signs and Symptoms on Visual Analog Scales (VAS)

Subject assessment of improvement of respiratory clinical signs and symptoms as indicated by the subject placing a mark on a 10 cm VAS scored 0 (better state of health) to 100 (poor state of health) for cough, dyspnea, sputum, hemoptysis, chest tightness, and nocturnal awakening. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).

Time frame:
Baseline, Month 3, and Month 6, Month 9, or Month 12 [EOT], and End of study ([EOS] EOT + 6 months)
Reported as:
Mean · scores on scale
Change From Baseline in Respiratory Clinical Signs and Symptoms on Visual Analog Scales (VAS)
scores on scaleVoriconazole
Cough Month 3 (n=30)-15.80 ± 33.40
Cough Month 6 (n=27)-19.63 ± 35.48
Cough Month 9 (n=20)-17.45 ± 43.01
Cough Month 12 (n=16)-30.13 ± 37.01
Cough EOS (n=20)-13.65 ± 41.31
Dyspnea Month 3 (n=30)-2.67 ± 24.22
Dyspnea Month 6 (n=27)-4.22 ± 25.16
Dyspnea Month 9 (n=20)-1.40 ± 24.66
Dyspnea Month 12 (n=16)-8.69 ± 25.15
Dyspnea EOS (n=20)1.75 ± 31.30
Sputum Month 3 (n=30)-8.03 ± 27.44
Sputum Month 6 (n=28)-14.86 ± 37.11
Sputum Month 9 (n=21)-12.62 ± 37.35
Sputum Month 12 (n=17)-26.47 ± 26.59
Sputum EOS (n=21)-13.67 ± 36.20
Hemoptysis Month 3 (n=30)-2.13 ± 28.05
Hemoptysis Month 6 (n=28)5.11 ± 27.41
Hemoptysis Month 9 (n=21)-4.52 ± 30.32
Hemoptysis Month 12 (n=16)-8.31 ± 31.44
Hemoptysis EOS (n=21)1.14 ± 20.72
Chest tightness Month 3 (n=30)0.03 ± 37.85
Chest tightness Month 6 (n=28)0.86 ± 29.83
Chest tightness Month 9 (n=21)-1.52 ± 33.03
Chest tightness Month 12 (n=17)-9.29 ± 31.27
Chest tightness EOS (n=20)-4.00 ± 22.31
Nocturnal awakening Month 3 (n=30)0.57 ± 29.33
Nocturnal awakening Month 6 (n=28)-2.86 ± 36.84
Nocturnal awakening Month 9 (n=21)-2.40 ± 31.13
Nocturnal awakening Month 12 (n=16)4.00 ± 31.45
Nocturnal awakening EOS (n=21)5.29 ± 41.96
Mean VAS Month 3 (n=30)-4.67 ± 18.29
Mean VAS Month 6 (n=27)-5.99 ± 20.82
Mean VAS Month 9 (n=20)-7.16 ± 24.31
Mean VAS Month 12 (n=15)-15.87 ± 20.67
Mean VAS EOS (n=19)-6.58 ± 20.43
SecondaryNumber of Subjects With Relapse

Relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \[TDM\] and or endoscopy) and mycologically (histology and or culture and or serology).

Time frame:
During the 6 months following EOT (EOT + 3 months, EOT + 6 months)
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryTime to Relapse After EOT

Time (months) to relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \[TDM\] and or endoscopy) and mycologically (histology and or culture and or serology).

Time frame:
During the 6 months following EOT (EOT + 3 months, EOT + 6 months)
Reported as:
Number · months

No measurements were reported for this outcome.

SecondaryGlobal Survival: Number of Subjects With an Outcome of Death

Number of subjects with an outcome of death (adverse event with a fatal outcome) through end of study.

Time frame:
Baseline through EOS (EOT + 6 months)
Reported as:
Number · participants
Global Survival: Number of Subjects With an Outcome of Death
participantsVoriconazole
Global Survival: Number of Subjects With an Outcome of Death5 (0.725 to 0.976)
Statistical analysis
  • Voriconazole · Kaplan-meier estimate overall survival: 0.850 · 95% CI 0.725 to 0.976Global survival rate calculated using Kaplan-Meier estimate of overall survival.
SecondaryChange From Baseline in Quality of Life (QOL): St. George's Hospital Respiratory Questionnaire

Subject administered questionnaire to measure improvement in QOL; 50 questions exploring 3 different areas: symptoms, impact on activity profile (activity), and impact on daily life (impacts). Each item in an area is weighted based on empirical data; scores range from lowest possible weight 0 to highest possible weight 100. Scores for each section and total score calculated using score calculation algorithms with higher scores indicating poor health. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).

Time frame:
Baseline, Month 3, and Month 6, Month 9, or Month 12 [EOT], and EOS (EOT + 6 months)
Reported as:
Mean · scores on scale
Change From Baseline in Quality of Life (QOL): St. George's Hospital Respiratory Questionnaire
scores on scaleVoriconazole
Symptoms Month 3 (n=35)-5.50 ± 22.53
Symptoms Month 6 (n=29)-3.32 ± 7.37
Symptoms Month 9 (n=19)0.96 ± 29.78
Symptoms Month 12 (n=17)-2.72 ± 23.80
Symptoms EOS (n=23)-6.84 ± 23.53
Activity Month 3 (n=31)-4.15 ± 17.72
Activity Month 6 (n=28)-9.43 ± 17.30
Activity Month 9 (n=18)-0.03 ± 18.04
Activity Month 12 (n=18)-5.88 (-10.98 to -0.78)
Activity EOS (n=23)-8.06 (-14.58 to -1.54)
Impacts Month 3 (n=33)-6.72 (-12.42 to -1.03)
Impacts Month 6 (n=28)-8.41 (-15.22 to -1.61)
Impacts Month 9 (n=20)-3.78 (-14.72 to 7.16)
Impacts Month 12 (n=18)-7.97 (-16.49 to 0.55)
Impacts EOS (n=21)-7.93 (-13.46 to -2.40)
Total Month 3 (n=35)-5.70 (-10.60 to -0.81)
Total Month 6 (n=30)-8.39 (-14.02 to -2.76)
Total Month 9 (n=20)-1.87 (-11.26 to 7.51)
Total Month 12 (n=18)-6.63 (-12.97 to -0.28)
Total EOS (n=24)-8.19 (-12.41 to -3.96)
SecondaryNumber of Subjects With Complete or Partial Radiological Response

Radiological response: based on chest TDM except for tracheo-bronchialaspergillosis which was assessed by bronchoscopy. Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.

Time frame:
Month 3, and Month 6, Month 9, or Month 12 [EOT]
Reported as:
Number · participants
Number of Subjects With Complete or Partial Radiological Response
participantsVoriconazole
Month 3 Complete response4
Month 3 Partial response9
EOT [LVA] Complete response6
EOT [LVA] Partial response14
SecondaryNumber of Subjects With Mycological Response of Eradication

Mycological response: eradication: absence of aspergillus species (spp) in bronchopulmonary samples: sputum, bronchial aspirate or bronchoalveolar lavage (BAL) (negative direct examination \[exam\] and negative culture), and negative histological exam when available; persistence (no eradication): presence of aspergillus spp in any relevant bronchopulmonary samples. Not done (presumed eradication): case reviewed by DRC for any mycological exams not performed to assess if case should constitute presumed eradication (no sputum due to clinical improvement).

Time frame:
Month 3, and Month 6, Month 9, or Month 12 [EOT]
Reported as:
Number · participants
Number of Subjects With Mycological Response of Eradication
participantsVoriconazole
Month 3 Eradication29
Month 3 Persistence3
Month 3 Not done (presume eradication)3
Month 6 Eradication26
Month 6 Not done (presume eradication)6
Month 9 Eradication14
Month 9 Not done (presume eradication)7
Month 12 Eradication15
Month 12 Not done (presume eradication)2
SecondaryNumber of Subjects With Complete or Partial Serological Response

Serological response: normalization (complete response) defined as return to normal values (≤ 1 arc); partial response defined as significant decrease but not complete (decrease of 2 or more arcs compared to baseline). Complete or partial response summarized as Improvement; based on arc values at visit compared to arc values at baseline (inclusion).

Time frame:
Month 3, and Month 6, Month 9, or Month 12 [EOT]
Reported as:
Number · participants
Number of Subjects With Complete or Partial Serological Response
participantsVoriconazole
Month 3 Improvement10
Month 6 Improvement14
Month 9 Improvement9
Month 12 Improvement8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voriconazole—21/48 (43.8%)33/48 (68.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventVoriconazole
HaemoptysisRespiratory, thoracic and mediastinal disorders5/48
General physical health deteriorationGeneral disorders2/48
BronchitisInfections and infestations2/48
PneumothoraxRespiratory, thoracic and mediastinal disorders2/48
Abdominal painGastrointestinal disorders1/48
Abdominal pain upperGastrointestinal disorders1/48
ConstipationGastrointestinal disorders1/48
VomitingGastrointestinal disorders1/48
CholecystitisHepatobiliary disorders1/48
Bronchitis haemophilusInfections and infestations1/48
Most frequent other events
Showing 10 of 14
Most frequent other events
EventVoriconazole
Visual impairmentEye disorders9/48
BronchitisInfections and infestations9/48
HaemoptysisRespiratory, thoracic and mediastinal disorders7/48
Vision blurredEye disorders6/48
InsomniaPsychiatric disorders6/48
Photosensitivity reactionSkin and subcutaneous tissue disorders6/48
ChillsGeneral disorders4/48
Gamma-glutamyltransferase increasedInvestigations4/48
ConstipationGastrointestinal disorders3/48
NauseaGastrointestinal disorders3/48

Baseline characteristics

Age Continuous
Age Continuous(years)Voriconazole
Mean57.27 ± 13.85
Sex: Female, Male
Sex: Female, Male(Participants)Voriconazole
Female19
Male29
08

Study locations

18 sites
  • Pfizer Investigational Site
    Nantes, Cedex 44093, France
  • Pfizer Investigational Site
    Angers Cedex, 49033, France
  • Pfizer Investigational Site
    Bobigny, 93000, France
  • Pfizer Investigational Site
    Brest Cedex, 29609, France
  • Pfizer Investigational Site
    Bris Sous Forges, 94640, France
  • Pfizer Investigational Site
    Caen Cedex, 14033, France
  • Pfizer Investigational Site
    Dinan Cedex, 22101, France
  • Pfizer Investigational Site
    Grenoble Cedex 09, 38043, France
  • Pfizer Investigational Site
    Lille Cedex, 59037, France
  • Pfizer Investigational Site
    Lyon Cedex, 69394, France
  • Pfizer Investigational Site
    Montpellier Cedex 5, 34295, France
  • Pfizer Investigational Site
    Paris Cedex 18, 75877, France
  • Pfizer Investigational Site
    Paris Cedex 20, 75970, France
  • Pfizer Investigational Site
    Paris, 75010, France
  • Pfizer Investigational Site
    Poitiers Cedex, 86021, France
  • Pfizer Investigational Site
    Reims Cedex, 51092, France
  • Pfizer Investigational Site
    Rouen Cedex, 76031, France
  • Pfizer Investigational Site
    Suresnes, 92150, France
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Jul 2005
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jan 7, 2010
Last update
Jan 20, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00159822
Lead sponsor
Pfizer
First posted
Sep 12, 2005
Start date
Jul 2005
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jan 7, 2010
Last update
Jan 20, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion